FDA data Registry peer set 1 peer FDA shortage listed

Alternatives to oxybutynin

FDA shortage status is active for oxybutynin; 1 same-class SPL records are listed below for registry comparison only.

Brand: Ditropan

Anticholinergic / Antispasmodic Prescription 1 alternative found

oxybutynin class peers while FDA lists an active shortage

oxybutynin (Ditropan) is on an FDA shortage listing while 1 other Anticholinergic / Antispasmodic SPL records remain in this registry peer set (class inventory 2). Labeled indication field for oxybutynin: This medicine treats overactive bladder.

Top FAERS reaction fields for oxybutynin total 11,432 reports across 10 reactions, set beside dicyclomine. Counts are exposure-weighted submissions, not per-patient risk.

About oxybutynin

Oxybutynin extended-release tablets help control an overactive bladder. It reduces the feeling of needing to go to the bathroom often.

Used for: This medicine treats overactive bladder. It helps with symptoms like needing to urinate frequently, feeling a sudden urge to urinate, and leaking urine. It can also treat overactive bladder in children 6 years and older caused by nerve problems.

1 Anticholinergic / Antispasmodic peers (wide set)

Compare oxybutynin vs dicyclomine side-by-side →

oxybutynin vs dicyclomine · FAERS reaction fields

FAERS top-reaction field "Fall" shows the widest count spread between oxybutynin and dicyclomine in this extract (914-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect oxybutynin dicyclomine
Fatigue 1,539 1,119
Fall 1,467 553
Nausea 1,211 1,251
Dizziness 1,144 688
Diarrhoea 1,079 1,193
Pain 1,077 1,003
Urinary Tract Infection 1,043 -
Headache 991 861

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

oxybutynin shortage vs Anticholinergic / Antispasmodic peer index

Shortage status

FDA shortage listing is active for oxybutynin (status: To Be Discontinued). Peer rows remain a registry index, not a switch guide.

Frequently Asked Questions

Does FDA list a shortage for oxybutynin while peers remain indexed?
Yes - oxybutynin matched an active FDA shortage listing (To Be Discontinued) while 1 other Anticholinergic / Antispasmodic SPL records remain in this peer index for field comparison only.

Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full oxybutynin profile →

Field note for oxybutynin: see also the generic vs brand label guide when reading Ditropan SPL strings.